Literature DB >> 11093042

The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female.

D M Sherer1, R Eliakim, O Abulafia.   

Abstract

Our objective was to present current data pertaining to the role of angiogenesis in the accumulation of peritoneal fluid in both benign conditions and in the development of malignant ascites in the female. To this goal, we conducted a computerized search to identify all relevant studies published in the English literature. MEDLINE, Current Contents and Index Medicus were searched utilizing the terms: angiogenesis, peritoneal fluid, ascites, vascular endothelial growth factor (VEGF), therapy and carcinoma through May 2000. Review of the literature supports that angiogenesis promoted by VEGF is associated with fluid accumulation in animal and human tumor effusions. Benign conditions involving accumulation of peritoneal fluid and associated angiogenesis in the female include ovulation, endometriosis and severe ovarian hyperstimulation syndrome. Malignant intra-abdominal conditions associated with increased VEGF activity include primary epithelial ovarian, gastric and colon carcinomas, omental and hepatic metastatic disease. Initial trials with antiangiogenic (angioinhibitor) therapy such as anti-VEGF antibodies, anti-VEGF receptor antibodies, tumor necrosis factor, and metalloproteinase inhibitors have been reported and antitumor activity observed in a limited number of patients with advanced (inoperable or metastatic) disease.

Entities:  

Mesh:

Year:  2000        PMID: 11093042     DOI: 10.1159/000010320

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  12 in total

1.  Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer.

Authors:  Daniel T Rein; Anne Kathrin Volkmer; Jens Volkmer; Ines M Beyer; Wolfgang Janni; Markus C Fleisch; Anne Kathrin Welter; Dirk Bauerschlag; Thomas Schöndorf; Martina Breidenbach
Journal:  Oncol Lett       Date:  2012-01-03       Impact factor: 2.967

2.  The clinical significance of vascular endothelial growth factor in malignant ascites.

Authors:  Na Zhan; Wei-Guo Dong; Jing Wang
Journal:  Tumour Biol       Date:  2015-10-13

3.  Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites.

Authors:  Daye Cheng; Bin Liang; Hong Kong
Journal:  Med Oncol       Date:  2011-05-10       Impact factor: 3.064

Review 4.  Malignant ascites: pathophysiology and treatment.

Authors:  Emanuel Cavazzoni; Walter Bugiantella; Luigina Graziosi; Maria Silvia Franceschini; Annibale Donini
Journal:  Int J Clin Oncol       Date:  2012-03-31       Impact factor: 3.402

5.  Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model.

Authors:  David Pépin; Zhong-Qi Shao; Geneviève Huppé; Andrea Wakefield; Chee-Wui Chu; Zahra Sharif; Barbara C Vanderhyden
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

Review 6.  Angiogenesis-related pathways in the pathogenesis of ovarian cancer.

Authors:  Nikos G Gavalas; Michalis Liontos; Sofia-Paraskevi Trachana; Tina Bagratuni; Calliope Arapinis; Christine Liacos; Meletios A Dimopoulos; Aristotle Bamias
Journal:  Int J Mol Sci       Date:  2013-07-30       Impact factor: 5.923

7.  VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody.

Authors:  Sachio Fushida; Katsunobu Oyama; Jun Kinoshita; Yasumichi Yagi; Kouichi Okamoto; Hidehiro Tajima; Itasu Ninomiya; Takashi Fujimura; Tetsuo Ohta
Journal:  Onco Targets Ther       Date:  2013-10-16       Impact factor: 4.147

8.  Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.

Authors:  Hop S Tran Cao; Michael Bouvet; Sharmeela Kaushal; Alex Keleman; Eric Romney; Ginna Kim; John Fruehauf; David K Imagawa; Robert M Hoffman; Matthew H G Katz
Journal:  Mol Cancer Ther       Date:  2010-07-06       Impact factor: 6.261

9.  Microbial infection, inflammation and epithelial ovarian cancer.

Authors:  Xiaohui Xie; Mengyuan Yang; Yiling Ding; Jianlin Chen
Journal:  Oncol Lett       Date:  2017-06-15       Impact factor: 2.967

10.  Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapy.

Authors:  Roni Oren; Yoseph Addadi; Lian Narunsky Haziza; Hagit Dafni; Ron Rotkopf; Gila Meir; Ami Fishman; Michal Neeman
Journal:  Int J Cancer       Date:  2016-06-20       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.